Invest in stocks of MVST, SBS, CARG and ATR to tap their high-efficiency levels.
ATR gains from its business transformation plan and healthy segmental performance.
Here is how AptarGroup (ATR) and Epiroc Aktiebolag Unsponsored ADR (EPOKY) have performed compared to their sector so far this year.
AptarGroup (ATR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
AptarGroup (ATR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ATR estimates second-quarter 2024 adjusted earnings per share of $1.56-$1.64.
AptarGroup (ATR) possesses solid growth attributes, which could help it handily outperform the market.
AptarGroup, Inc. (NYSE:ATR ) Q1 2025 Earnings Conference Call May 2, 2025 9:00 AM ET Company Participants Mary Skafidas - Senior Vice President, Investor Relations & Communications Stephan Tanda - President & Chief Executive Officer Vanessa Kanu - Executive Vice President & Chief Financial Officer Conference Call Participants George Staphos - Bank of America Ghansham Panjabi - Baird Matt Roberts - Raymond James Daniel Rizzo - Jefferies Matt Larew - William Blair Gabe Hajde - Wells Fargo Operator Ladies and gentlemen, thank you for standing by. Welcome to Aptar's 2025 First Quarter Results Conference Call.
AptarGroup (ATR) came out with quarterly earnings of $1.20 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago.
AptarGroup (ATR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AptarGroup is poised for growth in its Pharma and Closure segments, but challenges are expected in the Beauty segment. The prescription drug business is expected to drive revenue growth in the Pharma segment. Margin expansion anticipated from operational leverage, cost management, and premium product mix.
ATR's Q4 top line gains from improved performances of the Pharma and Closures segments.